TCL Archive Funding Opportunities: NIH seeks “visionary thinkers” for awards of $2.5 million over five years. NCI RFA available. January 23, 2004
TCL Archive Perjeta, Herceptin & Docetaxel Combination Extended Survival in HER2-Positive Disease December 28, 2012